


21. (Amended) A method for inhibiting activity of an alkaline phosphatase, said method comprising contacting the alkaline phosphatase with a compound of formula (I):



where:

$\text{A}^1$  and  $\text{A}^2$  are the same or different aryl groups collectively bearing at least one hydrophilic substituent;

$\text{E}^1$  and  $\text{E}^2$  are the same or different and are O, S, or  $\text{NR}^2$  (where  $\text{R}^2$  is H or a linear or branched  $\text{C}_1\text{-C}_{20}$  carbon containing group);

M is H or a pharmaceutically acceptable monovalent cation;

$\text{R}^1$  is a linear or branched, saturated or unsaturated,  $\text{C}_1\text{-C}_{20}$  carbon containing group;

Z is a single bond, a carbonyl,  $\text{CE}^3\text{E}^4$ , or  $\text{CR}^3\text{E}^4$ , where

$\text{E}^3$  and  $\text{E}^4$  are the same or different and are  $\text{OR}^4$ ,  $\text{SR}^4$ , and  $\text{NR}^4_2$ , where

$\text{R}^3$  is a linear or branched  $\text{C}_1\text{-C}_{20}$  carbon containing group, and

$\text{R}^4$  is H or a linear or branched  $\text{C}_1\text{-C}_{20}$  carbon containing group; and

n is 0 or 1,

or a pharmaceutically acceptable salt thereof.

29. (Amended) The method of claim 21 where the compound is 2'-phosphophloretin, 2'-thiophosphophloretin, 2'-aminophosphophloretin, 3-azido-2'-phosphophloretin, or 4-azido-2'-phosphophloretin or a pharmaceutically acceptable salt thereof.

47. (Amended) The method of claim 39 where the compound is 2'-phosphophloretin, 2'-thiophosphophloretin, 2'-aminophosphophloretin, 3-azido-2'-phosphophloretin, or 4-azido-2'-phosphophloretin or a pharmaceutically acceptable salt thereof.

68. (Amended) The method of claim 60 where the a compound is 2'-phosphophlorethin, 2'-thiophosphophlorethin, 2'-aminophosphophlorethin, 3-azido-2'-phosphophlorethin, or 4-azido-2'-phosphophlorethin or a pharmaceutically acceptable salt thereof.

In accordance with 37 C.F.R. § 1.121(c)(1)(ii), a marked-up version of the claims amended above showing the changes relative to the claims pending immediately prior to the present amendment is attached hereto in an addendum entitled "ADDENDUM TO AMENDMENT DATED JUNE 6, 2003". In this addendum, deletions are indicated by square brackets and insertions are indicated by underlining.

#### REMARKS

Claims 21-77 are pending in the subject application. Hereinabove, claims 21, 29, 47, and 68 have been amended. Therefore, the claims now under consideration are claims 21-77, as amended. In view of the above amendments and the following remarks, applicant respectfully requests reconsideration of the rejections set forth in the outstanding office action.

As a preliminary matter, applicant notes that the outstanding office action, in the paragraph bridging pages 2 and 3 thereof, states that "[t]his application currently names joint inventors." This is not the case. Only one inventor is named: Brian E. Peerce. Applicant respectfully requests that the PTO ensure that its records are correct in this regard.